EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?

Peter Balint-Kurti, Qingli Liu

Molecular Plant Pathology · 2025-03 · 26 (3)

DOI: 10.1111/mpp.70077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Plant Pathology, online erschienen am 19.03.2025. Verfasst von Peter Balint-Kurti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Plant Science Research Unit, USDA-ARS, Raleigh, NC, USA. Hauptthemen laut MEDLINE: Disease Resistance, Plants, Genetically Modified, Crops, Agricultural, Plant Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation, National Science Foundation of Sri Lanka.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is more than 40 years since the era of transgenic plants began and more than 30 years after the cloning of the first plant disease resistance genes. Despite extensive progress in our mechanistic understanding and despite considerable sustained efforts in the commercial, nonprofit, academic and governmental sectors, the prospect of commercially viable plant varieties carrying disease resistance traits endowed by biotechnological approaches remains elusive. The cost of complying with the regulations governing the release of transgenic plants is often cited as the main reason for this lack of success. While this is undeniably a substantial hurdle, other transgenic traits have been successfully commercialised. We argue that a significant portion of the challenges of producing crop varieties engineered for disease resistance is intrinsic to the trait itself. In this review, we briefly discuss the main approaches used to engineer plant disease resistance. We further discuss possible reasons why they have not been successful in a commercial context and, finally, we try to derive some lessons to apply to future efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ResistancePlants, Genetically ModifiedCrops, AgriculturalPlant DiseasesGenetic Engineering

Stichwörter der Autor:innen

GMOdisease resistancegenetic engineering

Autor:innen und Institutionen

  • Plant Science Research Unit, USDA-ARS, Raleigh, NC, USA.
  • Department of Entomology and Plant Pathology, North Carolina State University, Raleigh, NC, USA.
  • Seeds Research, Syngenta Crop Protection, LLC Research Triangle Park, Durnham, NC, USA.

Förderung

  • National Science Foundation
  • National Science Foundation of Sri Lanka

Zitieren

APA

Balint-Kurti, P., & Liu, Q. (2025). It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?. Molecular Plant Pathology, 26(3). https://doi.org/10.1111/mpp.70077

Vancouver

Balint-Kurti P, Liu Q. It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?. Molecular Plant Pathology. 2025;26(3). doi:10.1111/mpp.70077

BibTeX
@article{BalintKurti2025,
  author = {Balint-Kurti, Peter and Liu, Qingli},
  title = {It‘s Complicated: Why Are There So Few Commercially Successful Crop Varieties Engineered for Disease Resistance?},
  journal = {Molecular Plant Pathology},
  year = {2025},
  volume = {26},
  number = {3},
  doi = {10.1111/mpp.70077}
}
Kostenlos starten →